FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022302637> ?p ?o ?g. }

• W2022302637 endingPage "443" @default.
• W2022302637 startingPage "434" @default.
• W2022302637 abstract "Abstract: Background: Studying the interactions between xenoreactive antibodies, complement and coagulation factors with the endothelium in hyperacute and acute vascular rejection usually necessitates the use of in vivo models. Conventional in vitro or ex vivo systems require either serum, plasma or anti‐coagulated whole blood, making analysis of coagulation‐mediated effects difficult. Here a novel in vitro microcarrier‐based system for the study of endothelial cell (EC) activation and damage, using non‐anticoagulated whole blood is described. Once established, the model was used to study the effect of the characterized complement‐ and coagulation inhibitor dextran sulfate (DXS, MW 5000) for its EC protective properties in a xenotransplantation setting. Methods: Porcine aortic endothelial cells (PAEC), grown to confluence on microcarrier beads, were incubated with non‐anticoagulated whole human blood until coagulation occurred or for a maximum of 90 min. PAEC‐beads were either pre‐ or co‐incubated with DXS. Phosphate buffered saline (PBS) experiments served as controls. Fluid phase and surface activation markers for complement and coagulation were analyzed as well as binding of DXS to PAEC‐beads. Results: Co‐ as well as pre‐incubation of DXS, followed by washing of the beads, significantly prolonged time to coagulation from 39 ± 12 min (PBS control) to 74 ± 23 and 77 ± 20 min, respectively (P < 0.005 vs. PBS). DXS treatment attenuated surface deposition of C1q, C4b/c, C3b/c and C5b‐9 without affecting IgG or IgM deposition. Endothelial integrity, expressed by positivity for von Willebrand Factor, was maintained longer with DXS treatment. Compared with PBS controls, both pre‐ and co‐incubation with DXS significantly prolonged activated partial thromboplastin time (>300 s, P < 0.05) and reduced production of thrombin‐antithrombin complexes and fibrinopeptide A. Whilst DXS co‐incubation completely blocked classical pathway complement activity (CH50 test) DXS pre‐incubation or PBS control experiments showed no inhibition. DXS bound to PAEC‐beads as visualized using fluorescein‐labeled DXS. Conclusions: This novel in vitro microcarrier model can be used to study EC damage and the complex interactions with whole blood as well as screen ‘‘endothelial protective’’ substances in a xenotransplantation setting. DXS provides EC protection in this in vitro setting, attenuating damage of ECs as seen in hyperacute xenograft rejection." @default.
• W2022302637 created "2016-06-24" @default.
• W2022302637 creator A5003449416 @default.
• W2022302637 creator A5009703715 @default.
• W2022302637 creator A5025997348 @default.
• W2022302637 creator A5026359487 @default.
• W2022302637 creator A5036665264 @default.
• W2022302637 creator A5039037324 @default.
• W2022302637 date "2005-07-01" @default.
• W2022302637 modified "2023-10-11" @default.
• W2022302637 title "Endothelial cell protection and complement inhibition in xenotransplantation: a novel in vitro model using whole blood" @default.
• W2022302637 cites W1484110964 @default.
• W2022302637 cites W1501179348 @default.
• W2022302637 cites W1510595339 @default.
• W2022302637 cites W195569127 @default.
• W2022302637 cites W1969922813 @default.
• W2022302637 cites W1981911825 @default.
• W2022302637 cites W1983760495 @default.
• W2022302637 cites W1993363980 @default.
• W2022302637 cites W2007516625 @default.
• W2022302637 cites W2012574456 @default.
• W2022302637 cites W2018446808 @default.
• W2022302637 cites W2034837500 @default.
• W2022302637 cites W2037198722 @default.
• W2022302637 cites W2045503814 @default.
• W2022302637 cites W2048628798 @default.
• W2022302637 cites W2057632294 @default.
• W2022302637 cites W2059129193 @default.
• W2022302637 cites W2062210226 @default.
• W2022302637 cites W2063574167 @default.
• W2022302637 cites W2075471404 @default.
• W2022302637 cites W2079509981 @default.
• W2022302637 cites W2082607642 @default.
• W2022302637 cites W2086298451 @default.
• W2022302637 cites W2106352950 @default.
• W2022302637 cites W2113082455 @default.
• W2022302637 cites W2129057675 @default.
• W2022302637 cites W2137336518 @default.
• W2022302637 cites W2145002803 @default.
• W2022302637 cites W2155047167 @default.
• W2022302637 cites W2164495722 @default.
• W2022302637 cites W2170922592 @default.
• W2022302637 cites W2171678969 @default.
• W2022302637 cites W2181838255 @default.
• W2022302637 cites W2240432631 @default.
• W2022302637 cites W2302742252 @default.
• W2022302637 cites W4301101845 @default.
• W2022302637 doi "https://doi.org/10.1111/j.1399-3089.2005.00239.x" @default.
• W2022302637 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16202066" @default.
• W2022302637 hasPublicationYear "2005" @default.
• W2022302637 type Work @default.
• W2022302637 sameAs 2022302637 @default.
• W2022302637 citedByCount "25" @default.
• W2022302637 countsByYear W20223026372014 @default.
• W2022302637 countsByYear W20223026372015 @default.
• W2022302637 countsByYear W20223026372016 @default.
• W2022302637 countsByYear W20223026372017 @default.
• W2022302637 countsByYear W20223026372021 @default.
• W2022302637 crossrefType "journal-article" @default.
• W2022302637 hasAuthorship W2022302637A5003449416 @default.
• W2022302637 hasAuthorship W2022302637A5009703715 @default.
• W2022302637 hasAuthorship W2022302637A5025997348 @default.
• W2022302637 hasAuthorship W2022302637A5026359487 @default.
• W2022302637 hasAuthorship W2022302637A5036665264 @default.
• W2022302637 hasAuthorship W2022302637A5039037324 @default.
• W2022302637 hasConcept C111684460 @default.
• W2022302637 hasConcept C123012128 @default.
• W2022302637 hasConcept C126322002 @default.
• W2022302637 hasConcept C1491633281 @default.
• W2022302637 hasConcept C150903083 @default.
• W2022302637 hasConcept C159654299 @default.
• W2022302637 hasConcept C1621761 @default.
• W2022302637 hasConcept C16685009 @default.
• W2022302637 hasConcept C176999471 @default.
• W2022302637 hasConcept C185592680 @default.
• W2022302637 hasConcept C202751555 @default.
• W2022302637 hasConcept C203014093 @default.
• W2022302637 hasConcept C207001950 @default.
• W2022302637 hasConcept C26291073 @default.
• W2022302637 hasConcept C2777292125 @default.
• W2022302637 hasConcept C2778382381 @default.
• W2022302637 hasConcept C2778442404 @default.
• W2022302637 hasConcept C2778914503 @default.
• W2022302637 hasConcept C2779394231 @default.
• W2022302637 hasConcept C2911091166 @default.
• W2022302637 hasConcept C55493867 @default.
• W2022302637 hasConcept C71924100 @default.
• W2022302637 hasConcept C86803240 @default.
• W2022302637 hasConcept C89560881 @default.
• W2022302637 hasConcept C98274493 @default.
• W2022302637 hasConceptScore W2022302637C111684460 @default.
• W2022302637 hasConceptScore W2022302637C123012128 @default.
• W2022302637 hasConceptScore W2022302637C126322002 @default.
• W2022302637 hasConceptScore W2022302637C1491633281 @default.
• W2022302637 hasConceptScore W2022302637C150903083 @default.
• W2022302637 hasConceptScore W2022302637C159654299 @default.
• W2022302637 hasConceptScore W2022302637C1621761 @default.
• W2022302637 hasConceptScore W2022302637C16685009 @default.

• next